ObjectiveTo integrate network pharmacology prediction with multi-level experimental verification methods， and to explore in depth the therapeutic efficacy and potential mechanism of luteolin in treating gout. MethodsDatabases were used to obtain potential pharmacodynamic targets of luteolin. Protein-protein interaction （PPI） network construction and network pharmacology analysis techniques were used to screen key core targets of luteolin in gout treatment. Further biological function enrichment analysis and signaling pathway analysis were performed on these targets. Molecular docking simulation was used to calculate the binding energy between luteolin and potential core targets， clarifying the strength of their interactions. In the in vivo experiment for hyperuricemia， 48 mice were randomly divided into a blank group， a model group， an allopurinol group （5 mg·kg^-1）， and low-dose （10 mg·kg^-1）， medium-dose （30 mg·kg^-1）， and high-dose （90 mg·kg^-1） luteolin groups. For the first three days， the blank and model groups were gavaged with an equal volume of normal saline， while the allopurinol group and luteolin groups were gavaged with corresponding drugs. From day 4 onwards， modeling was performed by intraperitoneal injection at 12：00 daily （normal saline for the blank group， and oxonic acid potassium-hypoxanthine mixture for other groups， with 300 mg·kg^-1 for each group）. Gavage intervention was administered at 18：00 daily （normal saline for the blank/model groups， and corresponding drugs for the treatment groups） until day 7. After sampling， levels of serum uric acid （UA）， alanine aminotransferase （ALT）， and aspartate aminotransferase （AST） were measured. Levels of xanthine oxidase （XO） in the liver and kidney， ATP-binding cassette transporter G2 （ABCG2） and malondialdehyde （MDA） in the kidney， and superoxide dismutase （SOD） in the liver were determined. Renal HE staining was also performed. In the pharmacodynamic study of gouty arthritis， 36 rats were randomly divided into a blank group， a model group， a colchicine group （0.315 mg·kg^-1）， and low-dose （7 mg·kg^-1）， medium-dose （21 mg·kg^-1）， and high-dose （63 mg·kg^-1） luteolin groups. The model was established by vertically injecting 100 µL of 25 g·L^-1 monosodium urate suspension into the posterior lateral aspect of the right ankle joint （the blank group was injected with an equal volume of normal saline）， with repeated injections every two days for reinforcement. From day 2 after modeling， daily gavage administration was performed （normal saline for the blank/model groups， and corresponding drugs for the treatment groups） for a total of 16 days. During the experiment， ankle swelling and pain threshold were measured regularly. After sampling， levels of serum tumor necrosis factor-α （TNF-α）， interleukin-6 （IL-6）， and interleukin-1β （IL-1β） were determined. Ankle joints were subjected to HE， Masson， and safranin O-fast green staining， and HE staining was also performed on ankle synovial tissue and various organs. Western blot was used to determine the expression levels of key proteins in gout-related signaling pathways. ResultsNetwork pharmacology analysis predicted that luteolin may regulate over 20 core targets， such as XO， ABCG2， nuclear factor erythroid 2-related factor 2 （Nrf2）， and SOD， through acting on signaling pathways including NF-κB， phosphoinositide 3-kinase/protein kinase B （PI3K/Akt）， and ABC transporters， thereby affecting uric acid metabolism and inflammatory responses. In the hyperuricemia model， compared with the blank group， the model group showed significantly increased serum UA level， liver and kidney XO activity， renal ABCG2 expression， and liver SOD activity （P<0.01）. Compared with the model group， the high-dose luteolin group significantly reduced serum UA level （P<0.01）， inhibited liver and kidney XO activity （P<0.01）， and significantly increased renal ABCG2 expression and liver SOD activity （P<0.01）， effectively alleviating renal oxidative stress damage and improving renal histopathological status. In the gouty arthritis model， compared with the blank group， the model group showed significant ankle swelling， decreased pain threshold， and significantly increased levels of IL-6， IL-1β， and TNF-α in serum and synovial tissue （P<0.01）. The high-dose luteolin group significantly reduced ankle swelling， prolonged hot plate pain threshold， effectively decreased the levels of the above inflammatory factors in serum and synovial tissue （P<0.01）， and significantly improved ankle pathological damage， showing good analgesic and anti-inflammatory effects. Western blot results further confirmed that luteolin significantly upregulated Nrf2 protein expression and downregulated XO and nucleotide-binding oligomerization domain （NOD）-like receptor protein 3 （NLRP3） expression in animals. ConclusionLuteolin can improve symptoms of hyperuricemia and gouty arthritis， and its potential mechanism may be related to inhibiting XO activity， increasing ABCG2 and SOD levels， and regulating Nrf2-mediated oxidative stress-related pathways.

OBJECTIVE To establish a scientific， systematic， multi-dimensional performance management system for pharmacy practice， so as to improve the efficiency and quality of pharmacy practice performance management in public hospitals. METHODS Based on the four dimensions of the balanced scorecard theory， finance， customer， internal process， learning and growth， reference indicators for pharmacy practice performance management were summarized. The Delphi method was used to screen indicators， and the analytic hierarchy process was applied to determine the weights of indicators. A pharmacy practice performance management system was then constructed. Based on this system， action plans were formulated and implemented. The effectiveness was evaluated from two aspects： customer reviews and changes in pharmacy practice outcomes. RESULTS A total of 28 reference indicators were summarized， and a performance management system for pharmacy practice was constructed， consisting of 4 primary indicators， 9 secondary indicators， and 20 tertiary indicators. Compared with action plans implementation before， the satisfaction of clinical departments was significantly improved， and 11 pharmacy practice performance management indicators were optimized after implementation. CONCLUSIONS A scientific and systematic performance management system for pharmacy practice has been successfully established， which can provide a reference for the innovation of hospital pharmacy practice management and the high quality development of pharmacy practice.

Successful cloning through somatic cell nuclear transfer (SCNT) faces significant challenges due to epigenetic obstacles. Recent studies have highlighted the roles of H3K4me3 and H3K27me3 as potential contributors to these obstacles. However, the underlying mechanisms remain largely unclear. In this study, we generated genome-wide maps of H3K4me3 and H3K27me3 in mouse pre-implantation NT embryos. Our analysis revealed that aberrantly over-represented broad H3K4me3 domain and H3K27me3 signal lead to increased bivalent marks at gene promoters in NT embryos compared with naturally fertilized (NF) embryos at the 2-cell stage, which may link to relatively low levels of H3K36me3 in NT 2-cell embryos. Notably, the overexpression of Setd2, a H3K36me3 methyltransferase, successfully restored multiple epigenetic marks, including H3K36me3, H3K4me3, and H3K27me3. In addition, it reinstated the expression levels of ZGA-related genes by reestablishing H3K36me3 at gene body regions, which excluded H3K27me3 from bivalent promoters, ultimately improving cloning efficiency. These findings highlight the excessive bivalent state at gene promoters as a potent barrier and emphasize the removal of these barriers as a promising approach for achieving higher cloning efficiency.
Animals ; Mice ; Histone-Lysine N-Methyltransferase/biosynthesis* ; Histones/genetics* ; Nuclear Transfer Techniques ; Female ; Gene Expression Regulation, Developmental ; Promoter Regions, Genetic ; Epigenesis, Genetic ; Embryo, Mammalian/metabolism*

Objective:To compare the efficacy of transumbilical single-incision laparoscopic ovarian cystectomy versus multiport laparoscopic ovarian cystectomy in patients with ovarian cysts.Methods:Clinical data of 132 patients treated at Chengdu Third People's Hospital (January-December 2021) were retrospectively analyzed. Patients were divided into transumbilical single-incision laparoscopic ovarian cystectomy group ( n=70) and multiport laparoscopic ovarian cystectomy group ( n=62). Surgical parameters (operative time, blood loss, bowel recovery time, ambulation time, hospital stay), ovarian reserve function (LH, estradiol, FSH, AMH, inhibin B) both preoperatively and postoperatively, stress response (norepinephrine, cortisol), inflammatory markers (hs-CRP, IL-6, TNF-α), VAS pain scores at 24 h postoperative, scar satisfaction at 1 month and complication rates were compared between both group. Continuous data were expressed as xˉ± s, independent t-test was used on comparison between groups, while paired t-test was used on comparison before and after treatment, categorical data were expressed as n(%), χ2 test was used on comparison between groups. Results:The transumbilical single-incision laparoscopic ovarian cystectomy group had a shorter time on bowel recovery [(16.3±2.2) h vs. (20.8±3.0) h, t=9.87, P<0.001], ambulation [(12.9±2.6) h vs. (15.1±2.9) h, t=4.59, P<0.001] and hospitalization [(3.6±0.8) days vs. (5.3±1.1) days, t=9.65, P<0.001]. Both groups showed postoperative increases in LH, FSH, inhibin B, AMH [single-incision group: (13.2±3.4) U/L vs. (10.7±2.5) U/L, (9.4±1.6) U/L vs. (7.4±2.0) U/L, (66±13) μg/L vs. (44±8) μg/L, (5.2±1.2) μg/L vs. (1.7±0.4) μg/L, t values were 7.00、9.30、17.53、36.60, respectively, all P<0.001, multiport group: (14.1±3.6) U/L vs. (11.4±2.2) U/L, (9.8±1.8) U/L vs. (7.8±2.2) U/L, (62±15) μg/L vs. (43±8) μg/L, (4.9±1.1) μg/L vs. (1.7±0.4) μg/L, t values were 6.60、7.87、13.01、35.70, respectively, all P<0.001] and decreased estradiol [single-incision group: (304±29) pmol/L vs. (327±36) pmol/L, multiport group: (295±30) pmol/L vs. (329±37) pmol/L, t values were 5.92 and 7.99, respectively, both P<0.001], with no intergroup differences ( P>0.05). On postoperative day 1, the levels of serum NE, cortisol, hsCRP, IL-6, and TNF-α in both groups of patients were higher than those before surgery [single-incision group: (315±25) μg/L vs. (261±38) μg/L, (373±31) μg/L vs. (285±41) μg/L, (17.5±3.0) mg/L vs. (5.9±1.4) mg/L, (131±14) ng/L vs. (84±9) ng/L, (69±6) ng/L vs. (48±4) ng/L, t=14.34,20.45,44.11,34.19,35.14, respectively, all P<0.001; multiport group: (348±28) μg/L vs. (264±36) μg/L, (401±35) μg/L vs. (281±43) μg/L, (26.8±3.4) mg/L vs. (6.0±1.4) mg/L, (151±17) ng/L vs. (82±10) ng/L, (84±8) ng/L vs. (47±4) ng/L, t values were 20.67,25.74,68.24,40.24,48.56, respectively, all P<0.001], and the multiport group was higher than the single-incision group( t values were 7.12、4.94、16.89、7.60、11.54, respectively, all P<0.001). At 24 h postoperative, VAS scores was lower in transumbilical single-incision laparoscopic ovarian cystectomy group compared to multiport laparoscopic ovarian cystectomy group [(3.1±0.6) points vs. (4.3±0.9) points, t=4.41, P<0.001]. One month postoperative, scar satisfaction was higher in transumbilical single-incision laparoscopic ovarian cystectomy group compared to multiport laparoscopic ovarian cystectomy group [(21.0±1.5) points vs. (19.7±2.0) points, t=4.41, P<0.001].Difference on complications rate between groups was not statistically significant [14.3% (10/70) vs 21.0% (13/62), χ2=1.02, P=0.312]. Conclusion:Compared to multiport laparoscopy, transumbilical transumbilical single-incision laparoscopic ovarian cystectomy accelerates recovery, reduces pain, improves cosmetic outcomes, and minimizes surgical stress/inflammatory responses without compromising ovarian reserve or increasing complications.

Objective This study aims to investigate the current status and potential profiles of emotional inhibition in stoma patients with colorectal cancer,to analyze the differences and influencing factors,and thereby provide a basis for the development of intervention strategies.Methods A convenience sample of 348 colorectal cancer patients with ostomies was recruited from colorectal surgery departments and ostomy outpatient clinics of a tertiary A hospital in Anhui Province.Data were collected using the General Information Questionnaire,Emotional Inhibition Scale,Chinese Perceived Stress Scale,10 item Conner Davidson Resilience Scale,and Family Care Index Questionnaire.Latent profile analysis was performed using Mplus 8.3,while univariate analysis and multivariate logistic regression analysis were conducted using SPSS 26.0.Results Valid questionnaires were collected from 336 participants(response rate 96.6％).Colorectal cancer patients with ostomies demonstrated a mean emotional inhibition score of 30.84±10.49.Latent profile analysis identified 3 distinct emotional inhibition patterns:high inhibition-suppressive type(31.25％),moderate inhibition-adaptive type(39.88％),and low inhibition-excessive type(28.87％).Gender,residential location,household income per capita,ostomy self-care proficiency,perceived stress levels,psychological resilience scores and family functioning status emerged as significant determinants of emotional inhibition heterogeneity among colorectal cancer patients with ostomies across distinct latent profiles(P＜0.05).Conclusion Colorectal cancer patients with ostomies exhibit significant heterogeneity in emotional inhibition profiles.Clinicians should conduct early identification of these latent classes through standardized assessments and develop tailored interventions to improve emotional inhibition outcomes in this clinical population.

Objective:To investigate the efficacy and prognosis of biliary drainage via endoscopic retrograde cholangiopancreatography (ERCP) before steroid therapy in treating autoimmune pancreatitis (AIP) complicated with obstructive jaundice.Methods:A retrospective analysis was performed on clinical data of patients with AIP complicated with obstructive jaundice who received steroid therapy at the First Affiliated Hospital of Naval Medical University from 2010 to 2023. Patients were divided into a drainage group (receiving ERCP biliary drainage before steroid therapy) and a steroid group (receiving only steroid therapy). Short-term efficacy, long-term efficacy, hospitalization costs and postoperative complications of ERCP biliary drainage were compared between the two groups.Results:A total of 69 patients were included, with 32 in the drainage group, aged 62.78±11.21 years, which demonstrated significantly higher costs (34 816.57±11 688.85 yuan VS 16 518.50±6 544.37 yuan, t=7.0, P<0.001), with 25.00% (8/32) experiencing ERCP-related complications, compared with 37 patients in the steroid group, aged 55.41±2.15 years. There was no significant difference in hospitalization duration between the drainage group (10.38±4.56 days) and the steroid group (8.95±4.99 days, t=1.2, P=0.219). After 1 month of treatment, total bilirubin [118.5 (76.2, 309.3) μmol/L VS 48.7 (30.5, 148.4) μmol/L, U=1 728.5, P<0.001] and direct bilirubin [84.5 (47.7, 236.3) μmol/L VS 37.7 (18.3, 105.7) μmol/L, U=1 588.5, P=0.001] levels in the drainage group remained higher than those in the steroid group, while alanine aminotransferase levels were lower [74.0 (46.5,110.5) U/L VS 143.0 (51.0,253.5) U/L, U=769.0, P=0.006]. No significant differences were observed in these biochemical indices between the two groups at 4-month and 12-month follow-ups ( P>0.05). The recurrence rates were 28.1% (9/32) in the drainage group and 21.6% (8/37) in the steroid group, with no significant difference in recurrence rate between groups ( χ2=0.4, P=0.266). Conclusion:ERCP biliary drainage does not significantly improve long-term efficacy or reduce recurrence rates in AIP patients with obstructive jaundice. Instead, it increases the risk of postoperative complications and medical costs. Direct steroid therapy is safe and feasible for confirmed AIP with obstructive jaundice.

By collecting inspection results from medical device clinical trials from 2016 to 2023,to analyze and discuss common problems of clinical trials from both in vitro diagnostic reagents and medical devices,and propose the suggested mea-sures taken by participants in the clinical trial,so as to avoid similar problems occur and ensure the quality of clinical trials.

Objective This study aims to investigate the current status and potential profiles of emotional inhibition in stoma patients with colorectal cancer,to analyze the differences and influencing factors,and thereby provide a basis for the development of intervention strategies.Methods A convenience sample of 348 colorectal cancer patients with ostomies was recruited from colorectal surgery departments and ostomy outpatient clinics of a tertiary A hospital in Anhui Province.Data were collected using the General Information Questionnaire,Emotional Inhibition Scale,Chinese Perceived Stress Scale,10 item Conner Davidson Resilience Scale,and Family Care Index Questionnaire.Latent profile analysis was performed using Mplus 8.3,while univariate analysis and multivariate logistic regression analysis were conducted using SPSS 26.0.Results Valid questionnaires were collected from 336 participants(response rate 96.6％).Colorectal cancer patients with ostomies demonstrated a mean emotional inhibition score of 30.84±10.49.Latent profile analysis identified 3 distinct emotional inhibition patterns:high inhibition-suppressive type(31.25％),moderate inhibition-adaptive type(39.88％),and low inhibition-excessive type(28.87％).Gender,residential location,household income per capita,ostomy self-care proficiency,perceived stress levels,psychological resilience scores and family functioning status emerged as significant determinants of emotional inhibition heterogeneity among colorectal cancer patients with ostomies across distinct latent profiles(P＜0.05).Conclusion Colorectal cancer patients with ostomies exhibit significant heterogeneity in emotional inhibition profiles.Clinicians should conduct early identification of these latent classes through standardized assessments and develop tailored interventions to improve emotional inhibition outcomes in this clinical population.

By collecting inspection results from medical device clinical trials from 2016 to 2023,to analyze and discuss common problems of clinical trials from both in vitro diagnostic reagents and medical devices,and propose the suggested mea-sures taken by participants in the clinical trial,so as to avoid similar problems occur and ensure the quality of clinical trials.

Objective:To compare the efficacy of transumbilical single-incision laparoscopic ovarian cystectomy versus multiport laparoscopic ovarian cystectomy in patients with ovarian cysts.Methods:Clinical data of 132 patients treated at Chengdu Third People's Hospital (January-December 2021) were retrospectively analyzed. Patients were divided into transumbilical single-incision laparoscopic ovarian cystectomy group ( n=70) and multiport laparoscopic ovarian cystectomy group ( n=62). Surgical parameters (operative time, blood loss, bowel recovery time, ambulation time, hospital stay), ovarian reserve function (LH, estradiol, FSH, AMH, inhibin B) both preoperatively and postoperatively, stress response (norepinephrine, cortisol), inflammatory markers (hs-CRP, IL-6, TNF-α), VAS pain scores at 24 h postoperative, scar satisfaction at 1 month and complication rates were compared between both group. Continuous data were expressed as xˉ± s, independent t-test was used on comparison between groups, while paired t-test was used on comparison before and after treatment, categorical data were expressed as n(%), χ2 test was used on comparison between groups. Results:The transumbilical single-incision laparoscopic ovarian cystectomy group had a shorter time on bowel recovery [(16.3±2.2) h vs. (20.8±3.0) h, t=9.87, P<0.001], ambulation [(12.9±2.6) h vs. (15.1±2.9) h, t=4.59, P<0.001] and hospitalization [(3.6±0.8) days vs. (5.3±1.1) days, t=9.65, P<0.001]. Both groups showed postoperative increases in LH, FSH, inhibin B, AMH [single-incision group: (13.2±3.4) U/L vs. (10.7±2.5) U/L, (9.4±1.6) U/L vs. (7.4±2.0) U/L, (66±13) μg/L vs. (44±8) μg/L, (5.2±1.2) μg/L vs. (1.7±0.4) μg/L, t values were 7.00、9.30、17.53、36.60, respectively, all P<0.001, multiport group: (14.1±3.6) U/L vs. (11.4±2.2) U/L, (9.8±1.8) U/L vs. (7.8±2.2) U/L, (62±15) μg/L vs. (43±8) μg/L, (4.9±1.1) μg/L vs. (1.7±0.4) μg/L, t values were 6.60、7.87、13.01、35.70, respectively, all P<0.001] and decreased estradiol [single-incision group: (304±29) pmol/L vs. (327±36) pmol/L, multiport group: (295±30) pmol/L vs. (329±37) pmol/L, t values were 5.92 and 7.99, respectively, both P<0.001], with no intergroup differences ( P>0.05). On postoperative day 1, the levels of serum NE, cortisol, hsCRP, IL-6, and TNF-α in both groups of patients were higher than those before surgery [single-incision group: (315±25) μg/L vs. (261±38) μg/L, (373±31) μg/L vs. (285±41) μg/L, (17.5±3.0) mg/L vs. (5.9±1.4) mg/L, (131±14) ng/L vs. (84±9) ng/L, (69±6) ng/L vs. (48±4) ng/L, t=14.34,20.45,44.11,34.19,35.14, respectively, all P<0.001; multiport group: (348±28) μg/L vs. (264±36) μg/L, (401±35) μg/L vs. (281±43) μg/L, (26.8±3.4) mg/L vs. (6.0±1.4) mg/L, (151±17) ng/L vs. (82±10) ng/L, (84±8) ng/L vs. (47±4) ng/L, t values were 20.67,25.74,68.24,40.24,48.56, respectively, all P<0.001], and the multiport group was higher than the single-incision group( t values were 7.12、4.94、16.89、7.60、11.54, respectively, all P<0.001). At 24 h postoperative, VAS scores was lower in transumbilical single-incision laparoscopic ovarian cystectomy group compared to multiport laparoscopic ovarian cystectomy group [(3.1±0.6) points vs. (4.3±0.9) points, t=4.41, P<0.001]. One month postoperative, scar satisfaction was higher in transumbilical single-incision laparoscopic ovarian cystectomy group compared to multiport laparoscopic ovarian cystectomy group [(21.0±1.5) points vs. (19.7±2.0) points, t=4.41, P<0.001].Difference on complications rate between groups was not statistically significant [14.3% (10/70) vs 21.0% (13/62), χ2=1.02, P=0.312]. Conclusion:Compared to multiport laparoscopy, transumbilical transumbilical single-incision laparoscopic ovarian cystectomy accelerates recovery, reduces pain, improves cosmetic outcomes, and minimizes surgical stress/inflammatory responses without compromising ovarian reserve or increasing complications.